CLAIMS

1. A combination product comprising:

(i) a PPAR agonist; and

(ii) a FXR agonist.

2. The combination product according to claim 1, wherein the PPAR agonist is Elafibranor (ELA) or a pharmaceutically acceptable salt thereof.

3. The combination product according to claim 1 or 2, wherein the FXR agonist is Obeticholic acid (OCA) or a pharmaceutically acceptable salt thereof.

4. The combination product according to claim 1 or 2, wherein the FXR agonist is INT-767 or a pharmaceutically acceptable salt thereof.

5. The combination product according to any one of claims 1 to 4, wherein the combination product is a composition (i), (ii) and a pharmaceutically acceptable carrier.

6. The combination product according to any one of claims 1 to 4, wherein the combination product is a kit of parts comprising (i) and (ii).

7. The combination product according to any one of claims 1 to 6, wherein (i) and (ii) are at a synergistic effective amount for the treatment of a disease.

8. Use of:

(i) a PPAR agonist; and

(ii) a FXR agonist,

in the preparation of a combination for use in the treatment of an immune, inflammatory, metabolic, fibrotic or cholestatic disease.

9. The use according to claim 8, wherein the PPAR agonist is Elafibranor (ELA) or a pharmaceutically acceptable salt thereof.

10. The use according to claim 8 or claim 9, wherein the FXR agonist is Obeticholic acid (OCA) or a pharmaceutically acceptable salt thereof, or is INT-767 or a pharmaceutically acceptable salt thereof.

11. Use of the combination product according to any one of claims 1 to 6 in the preparation of a medicament for the treatment of an immune, inflammatory, metabolic, fibrotic or cholestatic disease.

12. The use according to claim 11, wherein the disease is NAFLD, NASH, liver fibrosis, liver cirrhosis, PBC or PSC.

13. The combination product according to any one of claims 1 to 7, for use in a method for the treatment of an immune, inflammatory, metabolic, fibrotic or cholestatic disease.

14. The combination product for use according to claim 13, wherein the disease is NAFLD, NASH, liver fibrosis, liver cirrhosis, PBC or PSC.

15. The use according to any one of claims 8 to 12, wherein:

- ELA is for administration at a dose comprised between 5 and 80 mg/day and OCA is for administration at a dose comprised between 7 and 17 mg/day;
- ELA is for administration at a dose comprised between 40 and 60 mg/day and OCA is for administration at a dose comprised between 5 and 12.5 mg/day;
- ELA is for administration at a dose comprised between 32 and 48 mg/day and OCA is for administration at a dose comprised between 4 and 10 mg/day;
- ELA is for administration at a dose comprised between 27 and 40 mg/day and OCA is for administration at a dose comprised between 3 and 8 mg/day;
- ELA is for administration at a dose comprised between 16 and 24 mg/day and OCA is for administration at a dose comprised between 2 and 5 mg/day; or
- ELA is for administration at a dose comprised between 8 and 12 mg/day and OCA is for administration at a dose comprised between 1 and 2.5 mg/day.

16. The combination product according to any one of claims 1 to 7, wherein:

- ELA is for administration at a dose comprised between 5 and 80 mg/day and OCA is for administration at a dose comprised between 7 and 17 mg/day;
- ELA is for administration at a dose comprised between 40 and 60 mg/day and OCA is for administration at a dose comprised between 5 and 12.5 mg/day;
- ELA is for administration at a dose comprised between 32 and 48 mg/day and OCA is for administration at a dose comprised between 4 and 10 mg/day;
- ELA is for administration at a dose comprised between 27 and 40 mg/day and OCA is for administration at a dose comprised between 3 and 8 mg/day;

- ELA is for administration at a dose comprised between 16 and 24 mg/day and OCA is for administration at a dose comprised between 2 and 5 mg/day; or

- ELA is for administration at a dose comprised between 8 and 12 mg/day and OCA is for administration at a dose comprised between 1 and 2.5 mg/day.

17. The combination product according to claim 13 or 14, wherein:

- ELA is for administration at a dose comprised between 5 and 80 mg/day and OCA is for administration at a dose comprised between 7 and 17 mg/day;

- ELA is for administration at a dose comprised between 40 and 60 mg/day and OCA is for administration at a dose comprised between 5 and 12.5 mg/day;

- ELA is for administration at a dose comprised between 32 and 48 mg/day and OCA is for administration at a dose comprised between 4 and 10 mg/day;

- ELA is for administration at a dose comprised between 27 and 40 mg/day and OCA is for administration at a dose comprised between 3 and 8 mg/day;

- ELA is for administration at a dose comprised between 16 and 24 mg/day and OCA is for administration at a dose comprised between 2 and 5 mg/day; or

- ELA is for administration at a dose comprised between 8 and 12 mg/day and OCA is for administration at a dose comprised between 1 and 2.5 mg/day.